The Role of Topical Timolol in the Treatment of Infantile Hemangiomas: A Systematic Review and Meta-analysis. by Khan, Maham et al.
A
ct
aD
V
A
ct
aD
V
A
d
v
a
n
c
e
s 
in
 d
e
rm
a
to
lo
g
y
 a
n
d
 v
e
n
e
re
o
lo
g
y
A
c
ta
 D
e
rm
a
to
-V
e
n
e
re
o
lo
g
ic
a
Acta Derm Venereol 2017; 97: 1167–1171
This is an open access article under the CC BY-NC license. www.medicaljournals.se/acta
Journal Compilation © 2017 Acta Dermato-Venereologica.
doi: 10.2340/00015555-2681
SPECIAL REPORT
1167
To date the efficacy and safety of topical timolol in 
the treatment of infantile hemangioma has not been 
reviewed and analysed systematically. We collated all 
published data on the efficacy and safety of topical 
timolol in the treatment of infantile hemangioma. A 
total of 31 studies with 691 patients were included. 
The fixed effects pooled estimate of the response rate 
defined as any improvement from baseline of infantile 
hemangioma after treatment with topical timolol was 
significant (RR = 8.96; 95% CI 5.07–15.47; hetero-
geneity test p = 0.99), and the treatment was overall 
well tolerated. However, the quality of evidence was 
low to moderate. Topical timolol is an effective treat-
ment for small infantile hemangioma, with no signifi-
cant adverse effects noted. However, there is still a 
need for adequately powered randomised controlled 
trials.
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Infantile hemangiomas (IHs) are benign proliferation of endothelial cells arising in the first 8 weeks of life 
as an area of telangiectasia or discoloration (1). IH are 
the most common benign tumours of infancy (2). Their 
life cycle is characterised by an early proliferative phase 
(6–12 months) followed by gradual involution, leading 
to complete regression in most cases (5–9 years) (1).
The incidence of IH in one-year-old children is estima-
ted to be 5 to 10% (3). Preterm infants with a birthweight 
of < 1,000 g have even a higher risk of 23% (4). There is 
female preponderance and predilection for Caucasians 
(5). Positive family history in first degree relatives and 
periconceptual use of drugs increases the risk of IH (6). 
Although most hemangioma occur sporadically, autoso-
mal dominant transmission has been reported (7). Old 
maternal age, placenta previa, and pre-eclampsia have 
been associated with IHs (8).There is an increased risk 
following amniocentesis and even a greater risk after 
chorionic villus sampling (CVS) (9). Embolization of 
angioblasts or endothelial cells from placenta to fetal 
skin during CVS might lead to multiple hemangiomas 
on the head, neck and thorax (10). 
While the majority of IHs regress spontaneously, ap-
proximately 10% require intervention (11). Typical indi-
cations for oral beta-blocker therapy include functional 
impairment (e.g. periocular IH causing amblyopia, nasal 
IH causing nose deformity, lip IH leading to feeding dif-
ficulties, and auricular IH causing deafness), and IH in 
life threatening anatomical locations (lung IH causing 
respiratory distress, obstructive subglottic IH, large 
cutaneous IH causing hepatic dysfunction and cardiac 
insufficiency) (11, 12). However, oral beta-blockers can 
have potential side-effects, such as a reduction in blood 
pressure and heart rate, even if the risk is small (13). 
Therefore, the topical application of a beta-blocker has 
been suggested as a suitable alternative, in particular for 
superficial IH (14). In 2010, Guo & Ni (15) presented 
the first report of successful topical timolol treatment 
in a resolving IH. Since then, several case reports and 
case series have claimed efficacy of topical timolol, 
making this a potential first-line agent for the treatment 
of superficial IH (13).
While there are American and European consensus 
guidelines for the use of oral beta-blockers (13, 16), 
there is still very little guidance on the optimal use of 
topical beta-blockers. To inform clinical practice and 
guidelines development, we therefore conducted a sys-
tematic review and meta-analysis of the literature on 
the efficacy and adverse effects of topical timolol for 
the treatment of IH.
METHODS
Registration, databases, and search strategy
This review was registered with the University of York Centre for 
Reviews and Dissemination (registration No. CRD42015019225), 
and we followed the PRISMA guidelines on the conduct of syste-
matic reviews throughout. The Cochrane Library, OVID Medline 
(1946–May 2015) and OVID Embase (1980–May 2015) databases 
were systematically searched for original publications using the 
following syntax: (hemangioma OR hemangiomas OR haemangi-
oma OR haemangiomas) AND (timolol OR beta-blocker OR beta 
blockers). All randomized controlled trials (RCTs), case-control 
studies, case series and case reports documenting the treatment 
response of IH to any preparation of topical timolol as mono-
therapy were eligible for inclusion. There was no restriction with 
regard to publication period, population size, or Fitzpatrick skin 
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type. Our outcomes were treatment efficacy of topical timolol 
in the resolution of IH (primary outcome) and adverse events of 
timolol as well as rebound growth after discontinuation of treat-
ment (secondary outcomes). Papers that did not document the 
clinical response to timolol and that were not available in English 
translation were excluded.
Study quality assessment 
The Cochrane Risk of Bias Assessment Tool for Non-Randomized 
Studies of intervention (ACROBAT-NRSI) was used to assess 
study quality (17), together with GRADEpro to create a summary 
of findings table (SoF). The quality of evidence for each predefined 
outcome was rated as ‘high’, ‘moderate’, ‘low’ or ‘very low’(18).
Statistical analysis 
Response rates and their corresponding 95% confidence inter-
vals (CI) were initially calculated for individual studies. Then 
fixed and random effects model were used to pool response rates 
across studies. The degree of heterogeneity across the trials was 
calculated using the I-squared ( I2) statistic and the p-value from 
the Q-statistic. Seven studies did either not have a control group 
(case series) or had a control arm with an additional treatment. 
To include those studies without a control group in the final meta-
analysis, we imputed a control group to each study by using the 
mean rate of improvement observed in the control arms of the 
3 best conducted studies included in the systematic review. The 
minimum number of individuals was used to reach this mean rate 
in the imputations, thus allowing for a large uncertainty.
RESULTS
Literature search 
After screening titles and abstracts of 406 articles by two 
independent assessors (MK and AB), 66 studies were 
selected for reading of the full text. Of the 66 studies, 31 
studies with 691 patients were included in the systematic 
review (15, 19–48) and 10 contained data that could be 
included in the meta-analysis (24, 25, 32–35, 39, 42, 46, 
48; Fig. 1). A GRADE assessment could be conducted 
on the 6 studies with comparator/control groups (23, 24, 
35, 36, 42, 48).
Study characteristics 
Unless otherwise stated, the studies used timolol opht-
halmic eye drops. Only one RCT compared topical 
timolol 0.5% BD (two times daily) with placebo (25). 
Two studies compared timolol with observation alone 
(24, 48), one study used topical timolol in conjunction 
with topical imiquimod (36), and one non-randomised 
study employed timolol together with PDL Nd:Yag la-
ser therapy (42). Another was a case report comparing 
timolol and propranolol in two separate patients (26). In 
two studies, IH was arbitrarily divided into two halves 
(49, 50). Timolol was applied to one-half and imiquimod 
to the other, or the other half acted as control site. These 
papers were excluded because there was no accurate 
way to prevent cross-contamination, and this is likely 
to have influenced the study outcome. Patient age when 
timolol was started ranged from 17 days to 13 months 
(mean age 4.02 months), with a majority being females 
(67.9%). Most were superficial IH (87.8%), except two 
case reports in which only deep IH were treated (41, 47). 
Most of the studies were done in Europe (12 studies) 
followed by the USA (8 studies) and Asia (6 studies), 
but participant ethnicity and Fitzpatrick skin type were 
often not specified. In 25 studies (80.6%) with 421 cases, 
timolol 0.5% was used. The 0.1% preparation was used 
in 5 studies with a total of 40 cases (23, 29, 39, 40, 44), 
whereas topical timolol 0.25% was used in only one study 
with 13 cases (24). Twenty-five studies with 170 cases 
used topical timolol BD and two studies applied topical 
timolol TDS (3 times daily) (152 cases) (37, 48). Timolol 
gel forming solution was used in 6 studies with 92 cases 
(23, 31, 32, 41, 44, 45). Moehrle et al. (32) manufactured 
a special timolol containing gel with timolol 0.5% eye 
drops 10.0 g and methyl hydroxypropyl cellulose 0.4 
g. The treatment dose was titrated up from 0.25 % to 
0.5% in one study (26). In all studies, treatment was on 
an outpatient basis with a mean duration of 4.11 months 
(range two weeks to 12 months). Primary indications 
for treatment were suspected functional and cosmetic 
disfigurement, risk of ulceration, infection, amblyopia 
and concern about adverse effects with other treatments.
Outcomes
Resolution of IH. All studies used different methods of as-
sessing the effectiveness of treatment. The hemangioma 
activity score (HAS) was utilized by two studies (34, 37). 
The result of the 3 studies using a visual analogue scale 
Fig. 1. Flow diagram of preferred reporting items for systematic 
review and meta-analyses for the systematic literature search.
Records identified through 
database searching  
(n = 395) 
Additional records identified 
through other sources  
(n = 11) 
 Duplicates removed  
(n = 123) 
Records screened  
(n = 283) 
Records excluded  
(n = 217) 
Full-text articles 
assessed for eligibility  
(n = 66) 
Full-text articles 
excluded, with reasons  
(n = 35) 
Combination therapy = 4 
Not English = 6 
Response to timolol not 
documented = 6 
Meetings and posters = 19 
Studies included in 
qualitative synthesis  
(n = 31) 
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(VAS) is shown in Fig. 2 (23, 36, 37). In the remaining 
studies, the clinicians visually assessed improvement and 
documented it as percentage improvement, with the aid 
of clinical photographs (Tables SI and SII1).
The clinical trial and two observational studies with 
untreated control groups had all relative risks (RR) > 1 
with overlapping CI (Fig. S11). A test for heterogeneity 
showed no statistical evidence of differences between 
these RR (p = 0.71, I2 =  0%), therefore we estimated the 
mean of these risk ratios with the technique known as 
“fixed effect model meta-analysis” obtaining an RR of 
9.04 (95% CI 3.22–25.41). We also estimated the mean 
rate of improvement only in untreated patients across 
these 3 studies (Fig. S21). This mean improvement was 
0.09 (9%) with no evidence of heterogeneity between 
studies (p = 0.71, I2 = 0%). We then imputed a control 
group in each of the other 7 studies that did not have 
it originally by including 11 untreated patients, one of 
which showed improvement. This assumes the same 
improvement rate than the mean in the observed studies 
(1/11 = 0.09) with the minimum possible sample size.
Finally, a meta-analysis of the RR between the two 
arms in all 10 studies with the imputed data produced a 
mean RR of 8.86 (95% CI 5.07–15.47) (Fig. 3), which 
is very similar to the RCT and the two non-randomised 
controlled studies. This analysis showed no evidence of 
heterogeneity (p = 0.99, I2 = 0%), and the random effects 
model produced very similar results.
Sleep disturbance was the only systemic adverse effect 
reported in two cases (23, 42). Rebound growth occurred 
in 4 patients from 3 studies (27, 32, 46). In 3 patients 
treatment was restarted, still leading to complete resolu-
tion of the IH (32, 46). The mean period of follow-up 
after discontinuation of treatment ranged from 3 to 6 
months in the studies that did report them. The majority 
of the studies reported no long-term follow-up. There 
were only 8 cases of deep IH, with complete resolution 
in 7 cases (23, 24, 41, 47). Unfortunately, the overall 
case numbers are too small to draw any firm conclusions 
with regard to potential differences in treatment response 
in relation to IH depth or size, age when treatment was 
started and treatment length and how this impacted on 
treatment response and rebound in the few cases where 
this was observed.
Risk of bias and GRADE assessment. The risk of bias 
could only be formally assessed in the 6 studies with 
control/comparator groups (Table SIII1) (23, 24, 35, 37, 
42, 48). The overall risk of bias was serious mainly due 
to confounding, selection of participants and lack of a 
per-protocol analysis. The GRADE outcome parameters 
were categorized as critical (treatment effect and adverse 
effects), important (resolution > 50% from baseline and 
complete resolution) and less important (rebound growth 
and parents’ assessed improvement with topical timolol) 
and are summarized in Table SIV1. The overall quality 
of evidence was moderate to low quality.
DISCUSSION
To the best of our knowledge, this is the first systematic 
review and meta-analysis focusing on topical timolol for 
the treatment of IH, summarising data from 31 studies 
with 691 patients. Topical timolol 0.5% is a promising and 
effective treatment modality, with a 91% resolution rate 
in pooled meta-analysis. The expected efficacy of control 
arms was estimated to be 9%, i.e., we would expect to see 
a mean of 9% clearance of IH in patients who received 
placebo or no treatment during the study. The degree of 
Fig. 2. Mean of visual analogue scale (VAS) percentage change from 
baseline of the 3 studies that used this outcome. The numbers in bold 
represent the mean VAS percentage of each study. Chakkittankandiyil et al. 
(23) reported that timolol 0.5% had more effect than timolol 0.1%. Qiu et 
al. (37) reported timolol 0.5% to be more effective than topical imiquimod.
1https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-2681
Fig. 3. Meta-analysis of all 10 studies, 
including imputed data from studies 
without control group. The meta-analysis of 
the relative risks (RR) between the two arms in 
all 10 studies with the imputed data produced a 
fixed effects estimate of 8.86 (95% confidence 
interval (CI), 5.07–15.47). This analysis showed 
no evidence of heterogeneity (p = 0.99, I2 = 0%).
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resolution was significantly greater in the treatment than in 
the non-treatment group. This further verifies the efficacy 
of topical timolol over placebo/observation.
We followed the PRISMA guidelines for systematic 
reviews. Study selection was performed independently 
by two authors, following a priory agreed data extraction 
protocol, which was published on the PROSPERO web-
site. The online search was supplemented by an extensive 
hand search of the literature. A key but unavoidable dif-
ficulty was the heterogeneity of the included studies with 
regard to dosing, duration of treatment, study endpoints 
and monitoring frequency. As a result, we had to combine 
the only RCT with observational study evidence. For the 
case series that did not have a control group we imputed 
the control group effect from controlled studies.
Lack of comparator groups limited formal GRADE 
assessment to only 6 studies. The quality of evidence 
was low to moderate quality. Bias in selection of parti-
cipants, lack of per-protocol analysis and confounding 
increased overall risk. However, the homogeneity of 
individual study results, in keeping with the only RCT 
(25), underlines the validity of our findings. 
Main weaknesses across all studies were the low 
number of participants and lack of long-term follow-up. 
Sleeping disturbance was the only reported side effect 
in 2/475 cases. Whether the sleeping disturbance was 
specifically due to topical timolol cannot be said with 
certainty, given how common this is in otherwise healthy 
infants, but the favourable side effect profile suggests that 
no specific side effect monitoring is required, different 
from oral beta-blocker therapy.
No side-effects were noted when topical timolol was 
applied on mucosal surfaces, like the lips or on ulcera-
ted areas. It is established that the greater viscosity of 
gel-forming solution potentially decreases the systemic 
absorption and leads to lower peak plasma concentration 
(0.28 ng/ml), but more information about the pharma-
cokinetics of topical timolol on hemangiomas is needed 
(51). 
Most studies used topical timolol 0.5% BD, and the 
medication is well-tolerated at this dose. The IH was 
completely resolved in 5 studies (40 cases) that used 
0.1% preparation (23, 29, 39, 40, 44). In the only study 
that used 0.25% topical timolol 12/13 cases responded 
(24). This information is not enough to make comparative 
assessment between different doses of topical timolol. 
In two studies, deep IH were exclusively considered and 
good response was documented in all 5 cases treated with 
topical timolol 0.5% BD (41, 47). But 5 is a small number 
of cases to extrapolate results from and more studies are 
required in this subgroup analysis. 
Although both the American and European consensus 
groups highlight the potential of topical timolol in trea-
ting IH, they do not provide guidelines on its use (13, 16). 
Our study provides validation on the efficacy and safety 
of topical timolol in the treatment of superficial IH. This 
can further support the development of future guidelines 
on the use of topical timolol in the treatment of IH (52). 
However, there is a need for a well-designed and 
adequately powered placebo-controlled RCT, using clear 
diagnostic criteria and validated outcome measures. 
Such a study should also explore the optimal duration of 
treatment and treatment strength as well  as the impact 
of IH size and depth on treatment response.
CONCLUSION
While the majority of IH do not require treatment as they 
spontaneously regress, a minority may require interven-
tion to prevent distressing complications.
Having looked at the evidence that has emerged since 
the first use of topical timolol, the inferences have been 
favourable. This study provides validation on the efficacy 
of topical timolol for superficial, localised, small and 
uncomplicated IH. Topical timolol also appears safe and 
well-tolerated, as no overt clinical evidence of adverse 
effects was noted. However, while topical timolol appears 
to be effective in particular for superficial IH, we caution 
against using it when systemic treatment is clearly war-
ranted due to functional impairment, anatomical location, 
size, or hepatic dysfunction and cardiac impairment.
This study highlights the need for a formal randomised 
control trail to further establish the efficacy of topical 
timolol over placebo/observation or other treatment mo-
dalities, and its long-term safety, monitoring, duration of 
treatment, dosing and appropriate indications for topical 
beta-blocker use. The findings in this study can also aid 
the formulation of treatment guidelines for IH.
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